Data Published in The Lancet Shows that CT-P13 is Non-inferior to Reference Infliximab in Inflammatory Bowel Disease
Celltrion Healthcare announced today that The Lancet has published the full data-set from its randomised controlled trial (RCT) of CT-P13 (biosimilar infliximab) in Crohn’s disease (CD), the PLANETCD Study. Results from the phase III study demonstrated the non-inferiority of CT-P13 to reference infliximab in biologic-naïve patients with moderate-to-severe CD.1
CT-P13 is already approved for the treatment of eight autoimmune diseases including CD, a form of inflammatory bowel disease (IBD), in more than 80 countries including the US, Canada, Japan and throughout Europe. This follows EMA approval in 2013 and FDA approval in 2016.
As per regulatory guidelines, approval of CT-P13 was based on proof of biosimilarity versus reference infliximab collected in clinical studies in patients with ankylosing spondylitis and rheumatoid arthritis that established equivalence of the drugs in pharmacokinetics (PK) and efficacy, as well as comparability in safety and immunogenicity.2 ,3 ,4 ,5 ,6 ,7 Approval of CT-P13 in IBD and other non-rheumatological indications was based on extrapolation, a process that allows approval of a biosimilar in a non-studied indication based on the totality of evidence.8, 9,10
These positive results from the CD RCT, build on the existing body of evidence in favour of CT-P13 and validate the extrapolation process on which the approval of CT-P13 was based on for the treatment of IBD.
“This is the first head-to-head study demonstrating the equal efficacy of an anti-TNF biosimilar in inflammatory bowel disease. The findings demonstrate that patients living with Crohn’s disease continue to experience comparable efficacy, pharmacodynamics, pharmacokinetics, safety and immunogenicity when switched to CT-P13 from reference infliximab. This robust evidence makes a compelling case for the use of biosimilars and will inform decision-making by gastroenterologists when choosing anti-TNF therapy for their patients,” said Professor Stefan Schreiber, Director of the Clinic for Internal Medicine at Kiel Campus of the University Hospital Schleswig-Holstein in Germany.
The 54-week RCT, involving 220 patients from 58 centres in 16 countries, showed comparable efficacy and safety profiles between all treatment groups (switched or continued groups) in patients with CD who had failed and/or were intolerant to non-biologic treatments.1
The study used the Crohn’s Disease Activity Index (CDAI), a measurement used to quantify the symptoms of CD patients in order to define response or remission of disease. The primary endpoint was set as the proportion of patients achieving a decrease of ≥ 70 points in CDAI from baseline to week 6. Non-inferiority of CT-P13 to reference infliximab with respect to response rates was established when the 95% confidence interval (CI) between the two drugs fell within the pre-specified margin.1
Mr Hyoung-Ki Kim, Vice Chairman at Celltrion Healthcare said: “The PLANETCD study is the first investigation of the therapeutic efficacy of an infliximab biosimilar powered to show non-inferiority to reference infliximab in inflammatory bowel disease. We at Celltrion Healthcare are proud to be the company leading the way in the biosimilar space as well as witness the growing recognition attributed to our products due to their high quality and cost effectiveness. This PLANETCD study published in The Lancet, together with the evidence from the influential NOR-SWITCH study, which was performed across multiple indications, support the equivalence between CT-P13 and reference infliximab.”
Notes to editors:
Additional quotes from physicians about the PLANETCD Study
“The study confirmed the validity of extrapolation for CT-P13 and add to the body of evidence supporting its use in patients with IBD,” said Professor Young Ho Kim, a global principal investigator of the study and professor of Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. “The non-inferior efficacy of CT-P13, measured by CDAI-70 response, was demonstrated as a primary endpoint after week 6, and comparable response rates were maintained up to week 54. Both efficacy and safety profiles were observed to be similar in all study arms including switching groups for a year.”
About inflammatory bowel disease
Inflammatory bowel diseases (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), are chronic disabling gastrointestinal disorders that impact every aspect of a patient’s life.11 They affect an estimated 5 million people globally;12 IBDs account for substantial costs to the healthcare system and society; the direct healthcare costs of IBDs are estimated to be €4.6-5.6 billion per year.13
About CT-P13 (biosimilar infliximab)
CT-P13 is developed and manufactured by Celltrion, Inc. and was the world’s first monoclonal antibody biosimilar approved by the European Commission (EC). It is indicated for the treatment of eight autoimmune diseases including rheumatoid arthritis and IBD. It was approved by the EC under the trade name Remsima® in September 2013 and launched in major EU countries in early 2015. The US FDA approved CT-P13 in April 2016 under the trade name Inflectra®. CT-P13 is approved in more than 89 countries (as of March 2019) including the US, Canada, Japan and throughout Europe.
About Celltrion Healthcare
Celltrion Healthcare is committed to delivering innovative and affordable medications to promote patients’ access to advanced therapies. Its products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US FDA cGMP and the EU GMP guidelines. Celltrion Healthcare endeavors to offer high-quality cost-effective solutions through an extensive global network that spans more than 120 different countries. For more information please visit: http://www.celltrionhealthcare.com/
About The Lancet medical journal
The Lancet is the world's leading independent general medical journal. The journal's coverage is international in focus and extends to all aspects of human health. The Lancet publishes the original primary research and review articles of the highest standard. The Lancet is stringently edited and peer-reviewed to ensure the scientific merit and clinical relevance of its diverse content. Drawing on an international network of advisers and contributors, The Lancet meets the needs of physicians by adding to their clinical knowledge and alerting them to current issues affecting the practice of medicine worldwide. The Lancet has an Impact Factor of 53.254.14
1 Byong Duk Y, et al. Efficacy and safety of
biosimilar CT-P13 compared with innovator infliximab in patients with
active Crohn’s disease: An international, randomised, double blind,
parallel-group, non-inferiority phase III study, The Lancet.
Available at http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)32196-2/fulltext
[Last accessed March 2019]
2 Yoo DH, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when co-administered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013;72(10):1613-20.
3 Yoo DH, et al. A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study. Arthritis Res Ther. 2016;18:82.
4 Yoo DH, et al. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. Ann Rheum Dis. 2017;76(2):355-363.
5 Park W, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013;72(10):1605-12.
6 Park W, et al. Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study. Arthritis Res Ther. 2016;18:25.
7 Park W, et al. Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study. Ann Rheum Dis. 2017;76(2):346-354.
8 Jung SK, et al. Physiochemical characterization of Remsima. MAbs 2014; 6: 1163-77.
9 United States Food and Drug Administration. CT-P13 (infliximab biosimilar) briefing document for the arthritis advisory committee. February 2016. Available from: https://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/arthritisadvisorycommittee/ucm484860.pdf [Last accessed March 2019]
10 European Medicines Agency. Assessment report: Remsima. June 2013. EMA/CHMP/589317/2013. Available from: https://www.ema.europa.eu/documents/assessment-report/remsima-epar-public-assessment-report_en.pdf [Last accessed March 2019]
11 Molodecky NA, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012; 142(1)46–54. Available at www.gastrojournal.org/article/S0016-5085 (11)01378-3/pdf [Last accessed March 2019]
12 The European Federation of Crohn’s & Ulcerative Colitis Associations. What is IBD? Science. Available at: www.efcca.org/en/science [Last accessed March 2019]
13 Burisch J, et al. The burden of inflammatory bowel disease in Europe. Journal of Crohn's and Colitis (2013)7,322-337.
14 The Lancet, Available at: https://www.journals.elsevier.com/the-lancet [Last accessed March 2019]
+44 203 817 6791
+44 203 817 6718
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Process Systems Enterprise: gPROMS FormulatedProducts 1.4 Includes Enhanced Capabilities Linking Digital Design to Digital Operations19.4.2019 07:58:00 CEST | Pressemelding
Process Systems Enterprise (PSE), the Advanced Process Modelling company, today released version 1.4 of gPROMS FormulatedProducts, the mechanistic model-based environment for integrated digital design of robust formulated products and their manufacturing processes, and related digital process operation. This release introduces major enhancements to both the gPROMS FormulatedProducts model libraries and the underlying gPROMS platform 6.0, including morphological crystallizer and sensor models to capture particle size and shape evolution, enhanced continuous direct compression models and improved wet granulation models. Platform enhancements include support for cluster computing, to significantly speed up execution of parameter estimation and other complex numerical solutions, and comprehensive global system analysis of dynamic systems for rapid exploration of the time-varying decision space and systematic risk and uncertainty analysis. Version 1.4 also introduces two key usability enhan
LOXAM Contributes to the Reconstruction of Notre Dame De Paris Cathedral19.4.2019 07:44:00 CEST | Pressemelding
In the wake of the Notre Dame de Paris blaze on Monday 15 April, Loxam the leading equipment rental company in Europe is playing its part in the reconstruction project of the partly destroyed cathedral. A rental operator in the construction equipment, LOXAM pledges to provide, free of charge, machines to the companies and tradesmen who will take part in these restoration works for the scheduled duration of five years. “Notre Dame de Paris Cathedral is the legacy of accomplished builders that we ought to preserve. As a committed rental operator, Loxam wishes to contribute to the rehabilitation of this monument by providing equipment for an overall 10-million € value over the upcoming five years” Gérard DEPREZ, President of LOXAM, indicates. With a fleet of over 200,000 machines, Loxam is meeting the needs of all tradesmen operating on this worksite. View source version on businesswire.com: https://www.businesswire.com/news/home/20190419005025/en/ Contact information PRESS : Virginie Ada
IFF to Release First Quarter 2019 Results May 618.4.2019 20:15:00 CEST | Pressemelding
Regulatory News: International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF), a leading innovator of scent, taste, and nutrition, announced that it will release its first quarter 2019 earnings results following the market close on Monday, May 6, 2019. The management team will host a live webcast on Tuesday, May 7, 2019 at 10:00 a.m. ET to discuss results and outlook with the investor community. Investors may access the live webcast and accompanying slide presentation on the Company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay. Meet IFF International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF) is a leading innovator of scent, taste, and nutrition, with 97 manufacturing facilities, 105 R&D centers, and 39,000 customers globally. At the heart of our company, we are fueled by a sense of discovery, constantly asking “what if?”. That passion for exploration dri
Gilead Sciences to Release First Quarter 2019 Financial Results on Thursday, May 2, 201918.4.2019 20:05:00 CEST | Pressemelding
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2019 financial results will be released on Thursday, May 2, after the market closes. At 4:30 p.m. Eastern Time, Gilead’s management will host a conference call to discuss the company’s financial results for the first quarter 2019 and provide a business update. The live webcast of the call can be accessed at the company’s Investors page at http://investors.gilead.com/. Please connect to the company’s website at least 15 minutes prior to the start of the call to ensure adequate time for any software download that may be required to listen to the webcast. Alternatively, please call 877-359-9508 (U.S.) or 224-357-2393 (international) and dial the conference ID 5259422 to access the call. Telephone replay will be available approximately two hours after the call through 8:00 p.m. Eastern Time, May 4, 2019. To access the replay, please call 855-859-2056 (U.S.) or 404-537-3406 (international) and dial the conference ID
Andersen Global Expands Africa Presence; Signs Collaboration Agreement in Economic Hub of South Africa18.4.2019 13:30:00 CEST | Pressemelding
Andersen Global is excited to announce the addition of its first collaborating firm in South Africa. Tabacks Attorneys and Corporate Law Advisors, headquartered in Johannesburg, South Africa, has signed a Collaboration Agreement with Andersen Global, an international association of member and collaborating firms. South Africa marks the tenth country in Africa in which Andersen Global has a presence. Led by Chairman David Woodhouse, Tabacks has a team of 27 lawyers who offer legal assistance and commercial advice to a diverse clientele in construction, manufacturing, energy, mining, explosives, retail, hospitality, logistics, pharmaceutical, property and banking industries. The firm is considered a leading law firm in South Africa, and its practice areas include competition law, commercial law, mining, employment law, environmental health & safety law, tax and litigation. “The global economy is rapidly changing, which brings unique challenges to corporate and commercial law,” said David
Amazon and Google Announce Official YouTube Apps to Launch on Fire TV; Prime Video App Coming to Chromecast and Android TV18.4.2019 13:00:00 CEST | Pressemelding
Today, Amazon (NASDAQ: AMZN) and Google (NASDAQ: GOOGL) announced that in the coming months, the two companies will launch the official YouTube app on Amazon Fire TV devices and Fire TV Edition smart TVs, as well as the Prime Video app for streaming to Chromecast and Chromecast built-in devices. In addition, Prime Video will be broadly available across Android TV device partners, and the YouTube TV and YouTube Kids apps will also come to Fire TV later this year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190418005212/en/ “We are excited to work with Amazon to launch the official YouTube apps on Fire TV devices worldwide,” said Heather Rivera, Global Head of Product Partnerships at YouTube. “Bringing our flagship YouTube experience to Amazon Fire TV gives our users even more ways to watch the videos and creators they love.” “We’re excited to bring the Prime Video app to Chromecast and Android TV devices, and to give our c